Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects
NCT03627767
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- 12 years of age or older with a minimum body weight of 40 kg
- Diagnosis of atopic dermatitis (AD) for at least 1 year and current status of moderate to severe disease (>= the following scores: BSA10%, IGA 3, EASI 16, Pruritus NRS 4)
- Recent history of inadequate response or inability to tolerate topical AD treatments or require systemic treatments for AD control
- Unwilling to discontinue current AD medications prior to the study or require
treatment with prohibited medications during the study
- Prior treatment with JAK inhibitors
- Other active nonAD inflammatory skin diseases or conditions affecting skin
- Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q
wave interval abnormalities, current or history of certain infections, cancer,
lymphoproliferative disorders and other medical conditions at the discretion of the
investigator
- Pregnant or breastfeeding women, or women of childbearing potential who are unwilling
to use contraception
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Caba,
- Bonn,
- Stuttgart,
- Kirov,
- Birmingham, Alabama
- Birmingham, Alabama
- Birmingham, Alabama
- Fountain Valley, California
- Long Beach, California
- Oceanside, California
- San Luis Obispo, California
- Santa Ana, California
- Santa Monica, California
- Bay Pines, Florida
- Boca Raton, Florida
- Coral Gables, Florida
- Miami, Florida
- Orange Park, Florida
- Tampa, Florida
- Macon, Georgia
- Normal, Illinois
- Skokie, Illinois
- Indianapolis, Indiana
- Indianapolis, Indiana
- Indianapolis, Indiana
- New Albany, Indiana
- Plainfield, Indiana
- Overland Park, Kansas
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Owensboro, Kentucky
- Owensboro, Kentucky
- Baton Rouge, Louisiana
- New Orleans, Louisiana
- Boston, Massachusetts
- Rochester, Minnesota
- Saint Joseph, Missouri
- Saint Louis, Missouri
- Saint Louis, Missouri
- Forest Hills, New York
- Rochester, New York
- Raleigh, North Carolina
- Bexley, Ohio
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Portland, Oregon
- Philadelphia, Pennsylvania
- Rapid City, South Dakota
- Dallas, Texas
- Fort Worth, Texas
- Houston, Texas
- Hurst, Texas
- Norfolk, Virginia
- Seattle, Washington
- Spokane, Washington
- La Plata, Buenos Aires
- Pilar, Buenos Aires
- Rosario, Santa FE
- C.a.b.a.,
- C.a.b.a.,
- C.a.b.a,
- Brussels,
- Bruxelles,
- Edegem,
- Curitiba, PR
- Rio de Janeiro, RJ
- Rio de Janeiro, RJ
- Rio de Janeiro, RJ
- Porto Alegre, RS
- Porto Alegre, RS
- Santo Andre, SP
- Santo Andre, SP
- Santo Andre, SP
- Sao Bernardo do Campo, SP
- Dupnitsa,
- Gabrovo,
- Sofia,
- Sofia,
- Sofia,
- Sofia,
- Varna,
- Calgary, Alberta
- Edmonton, Alberta
- Edmonton, Alberta
- Winnipeg, Manitoba
- St. John's, Newfoundland and Labrador
- Ajax, Ontario
- Barrie, Ontario
- Markham, Ontario
- Mississauga, Ontario
- Ottawa, Ontario
- Peterborough, Ontario
- Scarborough, Ontario
- Toronto, Ontario
- Waterloo, Ontario
- Windsor, Ontario
- Quebec,
- Santiago, Region Metropolitana ,
- Santiago, Region Metropolitana
- Santiago, Region Metropolitana
- Santiago, Region Metropolitana
- Santiago, Region Metropolitana
- Santiago, Region Metropolitana
- Santiago, Región Metropolitana
- Beijing, Beijing
- Chongqing, Chongqing
- Guangzhou, Guangdong
- Guangzhou, Guangdong
- Shenzhen, Guangdong
- Wuhan, Hubei
- Changsha, Hunan
- Changsha, Hunan
- Nanjing, Jiangsu
- Nanchang, Jiangxi
- Jinan, Shandong
- Shanghai, Shanghai
- Tianjin, Tianjin
- Hangzhou, Zhejiang
- Hangzhou, Zhejiang
- Hangzhou, Zhejiang
- Hangzhou, Zhejiang
- Beijing,
- Shanghai,
- Shanghai,
- Berlin,
- Berlin,
- Berlin,
- Bielefeld,
- Dresden,
- Erlangen,
- Essen,
- Gera,
- Halle,
- Hamburg,
- Hamburg,
- Hamburg,
- Hamburg,
- Hannover,
- Langenau,
- Luebeck,
- Beer Sheva,
- Haifa,
- Petah Tikva,
- Ramat-Gan,
- Tel-Aviv,
- Bologna, BO
- Modena, MO
- Roma, RM
- Chieti,
- Genova,
- Milano,
- Roma,
- Rome,
- Riga,
- Riga,
- Riga,
- Ventspils,
- Cuauhtemoc, Ciudad DE Mexico
- Cuautitlan Izcalli, Estado DE Mexico
- Cuernavaca, Morelos
- Monterrey, Nuevo LEON
- Aguascalientes,
- Chihuahua,
- Utrecht,
- Bydgoszcz,
- Gdansk,
- Gdansk,
- Katowice,
- Katowice,
- Katowice,
- Katowice,
- Krakow,
- Krakow,
- Krakow,
- Lodz,
- Lodz,
- Lodz,
- Lodz,
- Lublin,
- Ostrowiec Swietokrzyski,
- Szczecin,
- Tarnow,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Wroclaw,
- Wroclaw,
- Zabrze,
- Brasov, JUD. Brasov
- Cluj-Napoca, Jud. Cluj
- Bucuresti,
- Chelyabinsk,
- Kemerovo,
- Kirov,
- Moscow,
- Moscow,
- Rostov-on-Don,
- Ryazan,
- Saint-Petersburg,
- Saint-Petersburg,
- Saint-Petersburg,
- Saint-Petersburg,
- Saint-Petersburg,
- Saint-Petersburg,
- Saint-Petersburg,
- Smolensk,
- Belgrade,
- Nis,
- Pancevo,
- Banska Bystrica,
- Bratislava,
- Bratislava,
- Bratislava,
- Kosice-Saca,
- Kosice,
- Nitra,
- Svidnik,
- Badalona, Barcelona
- Esplugues de Llobregat, Barcelona
- Majadahonda, Madrid
- Alicante,
- Barcelona,
- Barcelona,
- Cordoba,
- Madrid,
- Madrid,
- Madrid,
- Madrid,
- Madrid,
- Sevilla,
- Valencia,
- Valencia,
- Kaohsiung,
- New Taipei City,
- Taichung,
- Tainan,
- Taipei,
- Taoyuan,
- Pardubice,
- Pardubice,
- Sidcup, Kent
- Shipley, WEST Yorkshire
- Birmingham, Alabama
- Birmingham, Alabama
- Huntington Beach, California
- Laguna Hills, California
- Long Beach, California
- Los Alamitos, California
- Mission Viejo, California
- Murrieta, California
- San Diego, California
- Santa Monica, California
- Santa Rosa, California
- Centennial, Colorado
- Cape Coral, Florida
- Coral Gables, Florida
- Coral Gables, Florida
- Doral, Florida
- Hialeah, Florida
- Jacksonville, Florida
- Largo, Florida
- Miami, Florida
- Tampa, Florida
- West Palm Beach, Florida
- West Palm Beach, Florida
- Columbus, Georgia
- Sandy Springs, Georgia
- Eagle, Idaho
- Nampa, Idaho
- Chicago, Illinois
- Normal, Illinois
- Skokie, Illinois
- Springfield, Illinois
- West Dundee, Illinois
- Plainfield, Indiana
- Louisville, Kentucky
- Baton Rouge, Louisiana
- Glenn Dale, Maryland
- Rockville, Maryland
- Rockville, Maryland
- Clarkston, Michigan
- Plymouth, Minnesota
- Hackensack, New Jersey
- Forest Hills, New York
- New York, New York
- Oceanside, New York
- Cary, North Carolina
- Cary, North Carolina
- Greensboro, North Carolina
- Statesville, North Carolina
- Winston-Salem, North Carolina
- Winston-Salem, North Carolina
- Cleveland, Ohio
- Oklahoma City, Oklahoma
- Tulsa, Oklahoma
- Clackamas, Oregon
- Medford, Oregon
- Medford, Oregon
- Portland, Oregon
- Philadelphia, Pennsylvania
- Anderson, South Carolina
- Charleston, South Carolina
- Greer, South Carolina
- Rapid City, South Dakota
- Arlington, Texas
- Austin, Texas
- Houston, Texas
- Webster, Texas
- West Jordan, Utah
- Franklin, Virginia
- Morgantown, West Virginia
- Phillip, Australian Capital Territory
- Maroubra, New South Wales
- Benowa, Queensland
- Woolloongabba, Queensland
- Box Hill, Victoria
- Carlton, Victoria
- East Melbourne, Victoria
- Parkville, Victoria
- Camberwell,
- Hectorville, South Australia,
- Pleven,
- Sofia,
- Sofia,
- Sofia,
- Sofia,
- Sofia,
- Sofia,
- Stara Zagora,
- Varna,
- Vancouver, British Columbia
- Winnipeg, Manitoba
- London, Ontario
- Markham, Ontario
- North Bay, Ontario
- Peterborough, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Regina, Saskatchewan
- Santiago, Region Metropolitana
- Santiago, Region Metropolitana
- Santiago, Region Metropolitana
- Santiago, Región Metropolitana
- Brno 2,
- Brno,
- Nachod,
- Nachod,
- Ostrava,
- Ostrava,
- Pardubice,
- Pardubice,
- Praha 10,
- Praha 1,
- Praha 2,
- Praha 2,
- Praha 2,
- Praha 3,
- Besancon,
- Bordeaux,
- Le Mans,
- Augsburg, Bavaria
- Leipzig, Saxony
- Bad Bentheim,
- Berlin,
- Bielefeld,
- Bonn,
- Dresden,
- Dresden,
- Frankfurt,
- Halle,
- Kiel,
- Langenau,
- Luebeck,
- Mahlow,
- Marburg,
- Muenster,
- Budapest,
- Debrecen,
- Debrecen,
- Gyula,
- Nyíregyháza,
- Püspökladány,
- Szeged,
- Veszprem,
- Zalaegerszeg,
- Modena, MO
- Roma,
- Ichikawa, Chiba
- Obihiro, Hokkaido
- Kobe, Hyogo
- Kamimashiki-gun, Kumamoto
- Habikino, Osaka
- Sakai, Osaka
- Chiyoda-ku, Tokyo
- Chuo-ku, Tokyo
- Shinjyuku-ku, Tokyo
- Fukuoka,
- Fukuoka,
- Saitama,
- Ansan-si, Gyeonggi-do
- Bucheon-si, Gyeonggi-do
- Daejeon,
- Incheon,
- Seoul,
- Seoul,
- Seoul,
- Riga,
- Riga,
- Riga,
- Riga,
- Ventspils,
- Cuauhtemoc, Mexico CITY
- Cuauhtemoc, Mexico CITY
- Monterrey, Nuevo LEON
- Monterrey, Nuevo LEON
- Queretaro,
- Bialystok,
- Chorzow,
- Czestochowa,
- Gdansk,
- Gdansk,
- Gdansk,
- Gdynia,
- Grodzisk Mazowiecki,
- Katowice,
- Katowice,
- Katowice,
- Katowice,
- Kielce,
- Krakow,
- Krakow,
- Krakow,
- Krakow,
- Ksawerow,
- Lodz,
- Lodz,
- Lublin,
- Lublin,
- Ostrowiec Swietokrzyski,
- Poznan,
- Poznan,
- Rybnik,
- Rzeszow,
- Rzeszow,
- Szczecin,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Wroclaw,
- Wroclaw,
- Wroclaw,
- Wroclaw,
- Bratislava,
- Kosice-Saca,
- Kosice,
- Nove Zamky,
- Svidnik,
- Badalona, Barcelona
- Alcorcon, Madrid
- Majadahonda, Madrid
- Majadahonda, Madrid
- Madrid,
- Valencia,
- Taipei, Taiwan (r.o.c)
- Taichung City,
- Taichung,
- Tainan,
- Taipei,
- Taipei,
- Wokingham, Berkshire
- Plymouth, Devon
- Romford, Essex
- London, Greater London
- Northwood, Middlesex
- Corby, Northamptonshire
- Yaxley, Peterborough
- Kenilworth, Warwickshire
- Glasgow,
Descriptive Information | |||||||
---|---|---|---|---|---|---|---|
Brief Title ICMJE | Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects | ||||||
Official Title ICMJE | A PHASE 3 RANDOMIZED WITHDRAWAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 IN SUBJECTS AGED 12 YEARS AND OVER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH THE OPTION OF RESCUE TREATMENT IN FLARING SUBJECTS | ||||||
Brief Summary | B7451014 is a Phase 3 study to investigate PF-04965842 in patients aged 12 years and over with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. Subjects responding well to an initial open-label 12 week treatment of PF-04965842 (200 mg) taken orally once daily (QD) will be identified and randomized in a double-blind manner to receive 200 mg QD PF-04965842, 100 mg QD PF-04965842, or QD placebo. Efficacy and safety of 2 doses of PF-04965842 will be evaluated relative to placebo over 40 weeks. Subjects experiencing significant worsening of their symptoms, i.e., protocol-defined flare, enter 12 weeks rescue treatment and receive 200 mg PF-04965842 together with a marketed topical medicine. Eligible patients will have the option to enter a long-term extension study after completing the initial 12 week treatment, the 12 week rescue treatment, and the 40 week blinded treatment. | ||||||
Detailed Description | Responder criteria for randomization at week 12 are defined as a) achieving an IGA of clear (0) or almost clear (1) (on a 5 point scale), b) a reduction from IGA baseline of 2 or more points, and c) reaching an EASI-75 response compared to baseline. Flare requiring rescue treatment is defined as a loss of at least 50% of the EASI response at Week 12 and an IGA score of 2 or higher. | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 3 | ||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment | ||||||
Condition ICMJE |
| ||||||
Intervention ICMJE |
| ||||||
Study Arms ICMJE |
| ||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Completed | ||||||
Actual Enrollment ICMJE | 1235 | ||||||
Original Estimated Enrollment ICMJE | 1370 | ||||||
Actual Study Completion Date ICMJE | October 7, 2020 | ||||||
Actual Primary Completion Date | September 2, 2020 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| ||||||
Sex/Gender ICMJE |
| ||||||
Ages ICMJE | 12 Years and older (Child, Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries ICMJE | Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, China, Germany, Israel, Italy, Latvia, Mexico, Netherlands, Poland, Romania, Russian Federation, Serbia, Slovakia, Spain, Taiwan, United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT03627767 | ||||||
Other Study ID Numbers ICMJE | B7451014 JADE REGIMEN ( Other Identifier: Alias Study Number ) 2018-000501-23 ( EudraCT Number ) REGIMEN ( Other Identifier: Alias Study Number ) | ||||||
Has Data Monitoring Committee | Yes | ||||||
U.S. FDA-regulated Product |
| ||||||
IPD Sharing Statement ICMJE |
| ||||||
Responsible Party | Pfizer | ||||||
Study Sponsor ICMJE | Pfizer | ||||||
Collaborators ICMJE | Not Provided | ||||||
Investigators ICMJE |
| ||||||
PRS Account | Pfizer | ||||||
Verification Date | January 2021 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |